Empyrean Capital Partners LP Buys Shares of 121,500 Charles River Laboratories International, Inc. $CRL

Empyrean Capital Partners LP bought a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 121,500 shares of the medical research company’s stock, valued at approximately $24,237,000.

Other large investors also recently added to or reduced their stakes in the company. Tema Etfs LLC acquired a new stake in Charles River Laboratories International during the 4th quarter valued at $26,000. Rothschild Investment LLC increased its stake in shares of Charles River Laboratories International by 82.4% in the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after acquiring an additional 84 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Charles River Laboratories International in the fourth quarter worth $42,000. Sfam LLC acquired a new position in shares of Charles River Laboratories International in the fourth quarter worth $43,000. Finally, Activest Wealth Management increased its stake in shares of Charles River Laboratories International by 10,900.0% in the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after acquiring an additional 218 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Trading Down 1.0%

Charles River Laboratories International stock opened at $182.97 on Thursday. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03. The company has a market capitalization of $8.81 billion, a price-to-earnings ratio of -48.66, a PEG ratio of 2.11 and a beta of 1.46. Charles River Laboratories International, Inc. has a one year low of $143.06 and a one year high of $228.88. The company’s fifty day moving average price is $174.31 and its two-hundred day moving average price is $182.64.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.96 by $0.10. The firm had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The business’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, analysts forecast that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CRL has been the topic of a number of research reports. Evercore reaffirmed an “outperform” rating and issued a $220.00 price target on shares of Charles River Laboratories International in a research note on Friday, May 8th. CLSA raised shares of Charles River Laboratories International from a “hold” rating to an “outperform” rating and upped their price target for the stock from $167.00 to $219.00 in a research note on Friday, May 29th. JPMorgan Chase & Co. dropped their price target on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Monday, April 13th. Weiss Ratings downgraded shares of Charles River Laboratories International from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Finally, Barclays upped their price target on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and an average target price of $211.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.